Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Follow-up Study of RSVPreF3 Maternal Vaccination in Subsequent Pregnancies
NCT05705440Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 23
01
Overview
Phase 3, open-label trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (4 arms), sponsored by GSK. Primary endpoints: Number of Maternal Participants With Pregnancy Outcomes, Number of Maternal Participants With Pregnancy-related Adverse Events of Special Interest (AESIs) and 1 more. Started Feb 2023; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05705440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705440.